Drug Trial Radar · NCT07621159
A Phase Ib/II Study of HDM2017 in Combination With Standard of Care in Advanced Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: Jun 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Jul 15, 2026
Primary completion
Nov 1, 2027
Study completion Nov 1, 2028
Sponsor
- Lead sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase Ib/II clinical study. All participants are patients with advanced colorectal cancer (CRC). The purpose of this study is to to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary anti-tumor efficacy of HDM2017 in combination with standard of care in patients with advanced CRC.
Conditions
- Colorectal Cancer Metastatic
Interventions
HDM2017Drug
Following a predefined dose and date.
FruquintinibDrug
Following a predefined dose and date.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Tolerated Dose (MTD)Time frame: 30 days after the last dose of IMP]
- Recommended Phase 2 Dose (RP2D)Time frame: 30 days after the last dose of IMP
- Type, incidence and severity of Adverse EventsTime frame: 30 days after the last dose of IMP
- Objective Response Rate (ORR)Time frame: 30 days after the last dose of IMP
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University Cancer Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.